Royce & Associates LP reduced its stake in shares of Quanterix Co. (NASDAQ:QTRX – Free Report) by 39.7% in the first quarter, according to its most recent filing with the SEC. The fund owned 255,348 shares of the company’s stock after selling 168,200 shares during the period. Royce & Associates LP’s holdings in Quanterix were worth $2,878,000 as of its most recent SEC filing.
Several other hedge funds have also added to or reduced their stakes in QTRX. Public Employees Retirement System of Ohio bought a new stake in Quanterix in the first quarter worth $29,000. Advisor Group Holdings Inc. increased its position in shares of Quanterix by 974.3% in the fourth quarter. Advisor Group Holdings Inc. now owns 2,890 shares of the company’s stock valued at $40,000 after acquiring an additional 2,621 shares during the period. PNC Financial Services Group Inc. increased its position in shares of Quanterix by 73.9% in the first quarter. PNC Financial Services Group Inc. now owns 1,845 shares of the company’s stock valued at $53,000 after acquiring an additional 784 shares during the period. Cutler Group LLC CA increased its position in shares of Quanterix by 2,489.0% in the first quarter. Cutler Group LLC CA now owns 5,178 shares of the company’s stock valued at $58,000 after acquiring an additional 4,978 shares during the period. Finally, Tower Research Capital LLC TRC increased its position in shares of Quanterix by 864.7% in the first quarter. Tower Research Capital LLC TRC now owns 6,338 shares of the company’s stock valued at $71,000 after acquiring an additional 5,681 shares during the period. 86.64% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
A number of equities analysts have issued reports on the stock. The Goldman Sachs Group boosted their price objective on shares of Quanterix from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Wednesday, August 9th. Leerink Partnrs upgraded shares of Quanterix from a “market perform” rating to an “outperform” rating in a research report on Tuesday, August 8th. Finally, SVB Securities upgraded shares of Quanterix from a “market perform” rating to an “outperform” rating and set a $30.00 price target on the stock in a research report on Tuesday, August 8th.
Quanterix Trading Down 0.3 %
QTRX traded down $0.08 during midday trading on Monday, reaching $24.45. The company’s stock had a trading volume of 103,853 shares, compared to its average volume of 337,824. The firm has a market capitalization of $918.10 million, a price-to-earnings ratio of -13.74 and a beta of 1.31. Quanterix Co. has a 1 year low of $8.02 and a 1 year high of $28.77. The stock’s 50-day moving average is $24.38 and its 200-day moving average is $18.95.
Quanterix (NASDAQ:QTRX – Get Free Report) last announced its quarterly earnings data on Monday, August 7th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.20. The business had revenue of $31.03 million for the quarter, compared to analysts’ expectations of $26.13 million. Quanterix had a negative net margin of 58.80% and a negative return on equity of 12.60%. As a group, equities research analysts forecast that Quanterix Co. will post -0.97 earnings per share for the current fiscal year.
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids.
- Five stocks we like better than Quanterix
- Do ETFs Pay Dividends? What You Need to Know
- An Electrifying New Upgrade for Tesla Leads the Market Higher
- How to Invest in Renewable Energy
- Oil Jumps, 2 Plastic Stocks About To Become Value Plays
- How to Invest in Biotech Stocks
- The Top 5 Analysts Calls in September
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.